Deltex Medical Regulatory News (DEMG)

3 Mar 2008 15:22

Deltex Medical Group PLC03 March 2008 Deltex Medical Group plc Independent analysis of clinical trial data further confirms clinical benefit of oesophageal Doppler-guided fluid delivery in abdominal surgery. 3 March 2008 - Deltex Medical Group plc ("Deltex Medical"), the UK's leadinghaemodynamic monitoring company, notes the publication of an article in theInternational Journal of Clinical Practice that examines the use of oesophagealDoppler monitoring (ODM) to guide fluid delivery in patients undergoing majorabdominal surgery. Doctors from the departments of surgery and anaesthesia at the CambridgeUniversity Hospitals NHS Trust examined results from the four previouslypublished randomised controlled clinical trials into the use of ODM in abdominalsurgery. The results, involving a total of almost 400 patients, were combinedusing the stringent statistical technique known as meta-analysis. The authors reported that use of ODM in abdominal surgery, based on the pooleddata analysed, resulted in significantly fewer post-operative complications anda consequent significant reduction in length of hospital stay. Deltex Medical's Chief Executive, Andy Hill commented: "This article further supports the growing belief that the use of DeltexMedical's CardioQ(TM) oesophageal Doppler monitor to guide fluid delivery should be routine clinical practice in abdominal and other major surgery." The full reference for the article is: Walsh SR, Tang T, Bass S and Gaunt ME. Doppler-guided intra-operative fluidmanagement during major abdominal surgery: systematic review and meta-analysisInt J Clin Pract. March 2008. 62, 3 466-470 For further information, please contact:- Deltex Medical Group plc 01243 774 837 Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 020 7554 1400 Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6000 Nominated AdvisorPhilip Davies philip.davies@csysecurities.comRussell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ(TM) monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • Proved that the CardioQ works in a wide range of surgical procedures • Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange